Key result
SGLT2 inhibitors reduce kidney disease progression ~17% vs. GLP-1RA and ns-MRA in CKD.
Why the study?
SGLT2i, GLP1a, and ns-MRA are promising treatments for chronic kidney disease, but their comparative efficacy, safety, and optimal role across endpoints needed comprehensive evaluation.
Do SGLT2i, GLP1a, and ns-MRA reduce cardiovascular and kidney disease risks in patients with chronic kidney disease?
Meta-Analysis (n=86,150)
Do SGLT2i, GLP1a, and ns-MRA reduce cardiovascular and kidney disease risks in patients with chronic kidney disease?
In patients with chronic kidney disease, SGLT2 inhibitors appear to provide the most favorable balance of efficacy and safety for reducing cardiovascular and kidney disease risks compared to GLP-1 receptor agonists and non-steroidal MRAs.
Answers are grounded in this paper and cite their sources.
Supports preferring SGLT2 inhibitors for kidney protection in CKD; extends network meta-analysis evidence of superiority over GLP-1 agonists and non-steroidal MRAs.
Sodium-glucose co-transporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP1a), and non-steroidal mineralocorticoid receptor antagonists (ns-MRA) are promising treatments for chronic kidney disease. This umbrella review of network meta-analyses evaluated their effects on cardiovascular outcomes, kidney disease progression, and adverse events, using the TOPSIS method to identify the optimal intervention based on P-scores. A total of 19 network meta-analyses and 44 randomized controlled trials involving 86,150 chronic kidney disease patients were included. Compared to placebo, SGLT2i were associated with reduced risks of cardiovascular events [Hazard ratio (HR): 0.776, 95% confidence intervals (CI): 0.727-0.998], kidney disease progression (HR: 0.679, 95% CI: 0.629-0.733), acute kidney injury (HR: 0.873, 95% CI: 0.773-0.907), and serious adverse events (HR: 0.881, 95% CI: 0.847-0.916). GLP1a and ns-MRA were also associated with significant reductions in cardiovascular and kidney-specific composite outcomes. Indirect evidence showed that SGLT2i demonstrated a lower risk of kidney disease progression compared to GLP1a (HR: 0.826, 95% CI: 0.716-0.952) and ns-MRA (HR: 0.818, 95% CI: 0.673-0.995), representing the best intervention across all endpoints. In conclusion, while SGLT2i, GLP1a, and ns-MRA all reduce cardiovascular and kidney disease risks in chronic kidney disease, SGLT2i appears to provide the most favorable balance of efficacy and safety.
No takes yet. Share an insight, caveat, or question.
Bellos et al. (2024) conducted a meta-analysis in chronic kidney disease (n=86,150). SGLT2i, GLP1a, and ns-MRA vs. Placebo was evaluated on Cardiovascular events (HR 0.776, 95% CI 0.727-0.998). SGLT2 inhibitors lowered the risk of kidney disease progression compared to GLP1a and ns-MRA in chronic kidney disease.
Synapse has enriched 10 related papers. Consider them for comparative context: